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Abstract
In 2016 the World Health Organization (WHO) called upon nations worldwide to eliminate viral hepatitis. 
Due to suboptimal hepatitis C virus (HCV) therapies in the past, many patients could not be treated or cured. 
With the current options, all patients can be treated and >90% is cured. However, these developments have not 
reached all patients, especially those who were lost to follow-up (LTFU) in previous years, an estimated 30% 
in the Netherlands. Retrieving these patients can contribute to HCV elimination. In light of this, we aimed 
to develop a nationwide retrieval strategy. During development we identified four major challenges. The first 
challenge is ethical and arises from the aim of the project: should physicians retrieve LTFU patients? We argue 
that the arguments in favour outweigh those against. The three other challenges are methodological and mainly 
legal in nature. Firstly, how far back are we allowed to trace LTFU patients? In the Netherlands, patient files 
should be kept for a minimum of fifteen years, but in chronic disease they may be archived longer. Secondly, 
which professional should identify the LTFU patients? Ideally this would be the treating physician, but we 
describe the circumstances that allow inclusion of assistance. Lastly, what is the proper way to invite the LTFU 
patients? We found that we can often request current address information from municipalities, and explain this 
process in detail. The offered solutions are feasible and translatable to other healthcare environments. We hope 
to take away any insecurities people may have about the ethical and legal nature of such a retrieval project and 
hope to inspire others to follow in our footsteps.
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Introduction
Hepatitis C virus (HCV) infection is a cause of liver disease 
that becomes chronic in 70%-75% of cases. Infection may 
result in life-threatening complications such as cirrhosis, 
hepatocellular carcinoma, and death. With 71 million 
people affected worldwide, global annual HCV mortality has 
increased in the past 15 years.1 In 2016, the World Health 
Organization (WHO) has set viral hepatitis elimination goals, 
which call for a 90% reduction in new chronic infections and 
a 65% reduction in mortality by 2030. Numerous countries, 
including the Netherlands, have agreed to comply with 
these goals. A Dutch national hepatitis plan was developed 
in 2016, focusing on five key areas of interest: (1) awareness 
and vaccination, (2) identification of infected patients, (3) 
diagnostics and treatment, (4) improved organization of 
hepatitis care and (5) surveillance of identified patients.
The third key area is of particular interest to us: diagnostics 
and treatment. Until 2014, the standard of care for chronic 
HCV patients was pegylated interferon with ribavirin, a 
lengthy, moderately effective and ill-tolerated treatment which 
cured only 40%-80% of patients. As a result, many patients 
had no treatment options or declined receiving treatment. In 
the Netherlands, it is estimated that ~30% of all diagnosed 
HCV patients have disappeared from care (lost to follow-up: 
LTFU).2,3 The advent of direct acting antivirals (DAAs) in 
2014 completely changed the therapeutic landscape of HCV. 
With an average treatment duration of 8-12 weeks, cure rates 
are >90%. The only remaining challenging group are patients 
with decompensated cirrhosis.4 Unfortunately, these novel 
therapeutic developments have not reached many LTFU 
patients. They are still at risk for liver related complications 
and would benefit greatly from reassessment. This calls for a 
systematic search for the LTFU population: retrieval.5 
In the past decade, numerous regional HCV retrieval 
projects have been carried out in the Netherlands. CELINE 
(‘Hepatitis C elimination in the Netherlands’) is the first 
nationwide approach and was developed based on these 
regional projects. This paper outlines the CELINE retrieval 
strategy which comes with various ethical and legal challenges. 
We aim to offer solutions and provide a legal framework for 
clinicians and researchers interested in retrieval. 
CELINE Methodology
As described in Figure, CELINE consists of four phases. 
In the first phase, laboratory records and patient charts are 
reviewed to identify patients who are LTFU. HCV antibody 
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tests, Western blots, RNA tests, and genotyping results are 
reviewed. We identify patients who are possibly chronically 
infected and patients who were chronically infected at the 
time of the last test. The first group consists of patients who 
have a positive anti-HCV test without a known RNA result. 
The second group consists of patients in whom the last RNA 
result was positive. Patients records from both groups will be 
reviewed to ascertain whether they are LTFU. 
The review of laboratory and patient records results 
in a cohort of LTFU patients. Patients residing in the 
Netherlands are invited via letter to be re-evaluated during 
phase 2. Patients who are 18 years or older are furthermore 
informed about the CELINE research project, which consists 
of patient file research. Patients are contacted by phone 1-2 
weeks afterwards to ascertain if they want to be re-evaluated. 
When patients do wish to be re-linked to care, their general 
practitioner is contacted and asked for a referral letter. 
Phase 3 consists of re-evaluating the LTFU patients. This 
re-evaluation is part of standard clinical care and serves no 
research purpose. If the patient wants to participate in the 
CELINE research project, consisting of patient file research, 
informed consent will be signed during this visit. Data on 
patient and disease characteristics and retrieval results of 
patients who have signed informed consent will be collected 
during phase 4. This data is pseudonymized and stored in a 
validated and Good Clinical Practice compliant web-based 
data management program, Castor EDC. Only the local 
physicians and/or researchers will have access to the local 
source file linking the codes to specific patients.
The primary outcome of the CELINE research project 
will be the total number of LTFU patients who have been 
successfully linked to care. Secondary outcomes include HCV 
prevalence, number of already successfully treated HCV 
patients, number of LTFU HCV-positive patients, reasons for 
LTFU and genotype prevalence, transmission route and liver 
fibrosis stage (progression) of the LTFU population.
We hypothesize that approximately 25% of ever-diagnosed 
patients is LTFU and that we will be able to link 25% of invited 
patients to care again. Estimating a diagnosed population of 
16 000, this corresponds to 4000 LTFU patients of whom 1000 
will be re-linked to care. 
Legal and Ethical Issues Arising During Development of 
CELINE
CELINE aims to identify LTFU chronic HCV patients and 
link them to care. The fundamental question that arises may 
be defined as follows:
1. Should physicians retrieve LTFU patients?
There are several arguments that favour retrieval. Hepatitis 
C infection causes liver related morbidity and mortality, 
and as a result an estimated 300 people die each year in the 
Netherlands.6 DAA treatment is fully reimbursed by Dutch 
healthcare insurance and offering treatment to LTFU patients 
has many advantages. First, the burden of disease can be 
lifted from symptomatic patients. Second, treatment curtails 
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development of complications. If patients were retained in 
care, worsening of their disease would have led to therapy. 
Since these patients became LTFU, we expect their disease 
to have progressed further compared to patients who were 
retained in care. Furthermore, we expect LTFU patients 
to have more additional risk factors for severe liver disease 
compared to the population retained in care, such as alcohol 
or drug use. Treating these patients prevents development of 
(further) morbidity and mortality, as was shown in a study 
of Willemse et al.7 Treating patients in an early stage of the 
disease may also offer an economical advantage. Successful 
treatment will prevent development of both extra-hepatic and 
hepatic complications, which otherwise would require long-
term and costly monitoring and/or treatment.8 A systematic 
review looking at modelling studies performed in the DAA 
era concluded that scale-up of treatment was generally cost-
effective compared to more restrictive treatment.9 The fourth 
advantage of treating LTFU patients is population-based. 
HCV transmission, though largely limited to specific risk 
groups in the Netherlands, still occurs in the current day 
and age. Treatment as prevention is an effective strategy. For 
example, HIV transmission can be prevented by antiretroviral 
therapy.10 In view of the presence of highly-effective DAAs, 
treatment as prevention is a realistic prospect. This is mostly 
the case in risk groups with ongoing transmission, such 
as men who have sex with men (especially HIV-positive 
men and pre-exposure prophylaxis users) and injecting/
intranasal drug users. In this case, retrieval serves to protect 
uninfected individuals. Finally there is a moral argument: 
the new therapeutic options are universally effective which 
is a paradigm with the situation when they left care. Many 
physicians will feel morally and ethically obliged to inform 
patients about the greatly improved outlook. Retrieval itself 
does not violate the patient’s ‘right not to know,’ since they 
have already received their HCV diagnosis in the past.
However, there are also counter arguments against retrieval. 
Firstly, since patients are no longer in care, physicians are not 
contractually obliged to re-establish contact with patients 
who are not currently being seen in their practice. On the 
other hand, if the arguments in favour of retrieval outweigh 
the potential disadvantages one could argue that there is 
no reason to refrain from participation. Thus, healthcare 
providers would be technically bound to retrieval, which 
would result in a situation where non-participating hospitals 
would be liable. If we did choose to start to retrieve LTFU 
patients suspected of chronic hepatitis C, we might want to 
extend retrieval projects to other disorders. However, it is 
difficult to identify robust criteria for disorders that merit 
retrieval and we run the risk that the line which distinguishes 
retrievable from non-retrievable disorders will get blurred 
easily. Chronic hepatitis C infection only causes complications 
after a protracted period of time in a limited subset of people. 
Thus, there is no clinical emergency situation requiring 
physicians to act immediately in order to avoid an acute 
and major health hazard. Lastly, retrieval could be seen as a 
violation of the patient’s autonomy, or a certain ‘right to be 
left alone.’ This autonomy could be overlooked relative to the 
public health advantage that retrieval provides. However, it is 
possible to curtail HCV transmission in other ways, such as 
education and improving awareness. 
In their 2016 report, the Dutch Health Council advised 
the minister of Health, Welfare and Sport on screening and 
retrieval of hepatitis B and C.11 The Council favoured retrieval 
of LTFU HCV patients and indicated that this strategy is an 
integral part of the (after) care for diagnosed HCV patients. 
The advice by the Council has been endorsed by the minister 
of Health. 
In light of all these arguments, we think that physicians have 
a legal and moral right to retrieve their LTFU chronic HCV 
patients, though they are not legally or morally bound to do 
so. Even though the cost-saving argument does not outweigh 
the patient’s autonomy in our opinion, we do not feel that 
retrieval threatens this autonomy. These patients have been 
diagnosed before and the information given during retrieval 
is noncommittal. The final argument in favour of a retrieval 
strategy is that CELINE has scientific aims. Within this scope, 
physicians-researchers are allowed to retrieve LTFU patients, 
as long as there is a clear protocol that has been approved by 
the appropriate regulatory bodies. 
In summary, we conclude that retrieval of chronic HCV 
patients is possible from an ethical and/or legal perspective, 
when performed in a structured manner. We will now address 
the accompanying legal challenges.
Legal and Ethical Issues Arising During Development of 
CELINE Methodology
CELINE aims to identify LTFU patients by retrospectively 
reviewing medical records. One of the first questions that 
arises is:
1. How far in the past is CELINE allowed to look in order to 
identify LTFU patients?
The Dutch Medical Treatment Contracts Act (WGBO) article 
454 states that medical records should be kept for a minimum 
period of 15 years.12 However, this period can be elongated in 
case of chronic conditions. CELINE therefore aims to review 
these records as far back as possible. In other countries, the 
time span that caregivers should store medical records may 
vary. However, we would advise them to also review their 
records as far back as possible.
In CELINE, we chose to identify patients based on laboratory 
records, since the Netherlands lacks a national registry in 
which all diagnosed patients are registered. Using laboratory 
records ensures that we miss no patients, since the diagnosis 
is made based on blood test results. However, some countries 
might not be able to use laboratory records. Countries that 
have a national hepatitis registry, might consider identifying 
their patients using this database as an interface. Otherwise, 
the use of diagnostic coding systems, like the International 
Classification of Disease, might provide a good alternative.
A medical microbiologist will produce a list of all HCV 
tests performed. Microbiologists are allowed to share this list 
with other physicians, since they are regarded as a member of 
the treatment team according to article 457 of the WGBO,12 
which is endorsed by the Dutch Health Council.11 Legislation 
may vary in other countries. When microbiologists are 
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not allowed to share their list of possible LTFU patients, 
they could theoretically retrieve these patients themselves. 
However, retrieval based on only laboratory results will likely 
result in contacting many patients who are already cured or 
still in care. 
The laboratory records will be reviewed in order to select 
patients in whom the last test result was positive, indicating 
that they were still infected when they left care. Hereafter, 
chart review is performed in order to ascertain LTFU status. 
This two-step selection process gives rise to the following 
challenge: 
2. Who should perform selection of laboratory records and 
chart review in order to identify LTFU patients?
The information that has to be reviewed contains personal 
data, which is privileged information only divulged to 
members of the treatment team. Unfortunately, previous 
regional retrieval efforts showed that the reviewing of this 
data is a time-consuming process. It would be valuable if an 
external party could review the records and identify LTFU 
patients. However, this idea needs careful exploration.
The WGBO states that in order to access a patient’s medical 
records, the patient has to give permission.12 However, the 
WGBO has introduced an exception if obtaining permission 
is impossible. In the case of CELINE, hundreds of patients 
would have to be contacted by their treating physician to 
ask permission to review their medical files. This would 
require an extraordinary amount of time and effort. The main 
condition for not obtaining the patient’s permission is stated 
in article 458 of the WGBO: the patient’s privacy must not 
be disproportionately compromised. As a consequence the 
external party has to be trained in medical confidentiality and 
patient privacy. The external party must sign a confidentiality 
agreement prior to record review. Only data pertaining the 
LTFU status of the patient should be reviewed. Identifiable 
data should not be collected of patients who cannot be invited 
for re-evaluation (eg, deceased patients) or who have actively 
objected against the exchange of their medical records. 
Identifiable data of patients who object to re-evaluation should 
be removed. Finally, these privacy-protecting measures have 
to be reviewed by the institutional review board, which should 
give a final ruling and monitor the process.
In other countries, legislation may vary. If an external 
party was not allowed to review patient records without 
prior permission, there are several options. In any case, 
the laboratory records would have to be reviewed by a 
microbiologist first, to identify patients that might be LTFU. 
Subsequently there are two options. First comes the option 
for a member of the treatment team to review the records. 
The second option is to ask permission of patients to review 
their records. This requires pre-emptive contact with the 
individual patients, which presents an opportunity to offer 
them re-linkage to care immediately, without reviewing their 
medical records first. However, it is likely that many patients 
who are contacted are already cured or still in care.
After identification of the LTFU patients, the patient will be 
invited for re-evaluation.
3. What is the best way to invite patients?
The safest way to reach LTFU patients is by written invitation, 
if the sender is sure that the address is correct. In case of LTFU 
patients, address information might not have been updated for 
years. Therefore we obtain current address information from 
the Municipal Personal Records Database (Basisregistratie 
Personen, BRP) when possible. Each person residing in the 
Netherlands for at least four months is obligated to enlist in the 
BRP. Organizations of public or social importance can request 
authorization to obtain this information, as is stated in article 
3.2 of the Personal Records Database Act.13 Hospitals for 
instance request authorization in view of optimal patient care 
or for medical research. In hospitals that do not have access 
to the BRP, CELINE collaborators should make a reasonable 
effort to ascertain the current address for their LTFU patients. 
This also applies to caregivers in other countries, who cannot 
request address information from municipalities. We advise 
them to contact other healthcare providers of the patient 
to retrieve the patient’s address. In CELINE for example, 
we contact their general practitioner. If the patient is not 
in contact with any known healthcare provider, a test letter 
could be sent to the last known address, without mentioning 
hepatitis C. If caregivers cannot ascertain the current address 
for the patient, the invitation should not be sent. 
Conclusion
Retrieval of LTFU patients should only be executed when the 
benefits outweigh the disadvantages, as is the case in chronic 
hepatitis C. CELINE is the first nationwide retrieval project in 
the Netherlands. We have identified four major challenges of 
ethical and legal nature. We believe that these challenges can 
be translated to both HCV- and non-HCV-related retrieval 
projects. We have provided solutions that can be used in 
the Netherlands and other countries, showing that retrieval 
can be done when done carefully. We hope to take away any 
insecurities people may have about the ethical and legal nature 
of retrieval projects in the Netherlands and hope to inspire 
healthcare professionals and policy-makers in other countries 
to develop their own retrieval strategy that accommodates 
their healthcare and legal system.
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